Inhouse product
Indications
Monas is indicated
for:
* রেজিস্টার্ড চিকিৎসকের পরামর্শ মোতাবেক ঔষধ সে'বন করুন
Pharmacology
Montelukast is a
selective and orally active leukotriene receptor antagonist that inhibits the
cysteinyl leukotriene receptor (CysLT1). The cysteinyl leukotrienes (LTC4,
LTD4, LTE4) are products of arachidonic acid metabolism and are released from
various cells, including mast cells and eosinophils. Cysteinyl leukotrienes and
leukotriene receptor occupation have been correlated with the pathophysiology
of asthma & allergic rhinitis, including airway edema, smooth muscle contraction,
and altered cellular activity associated with the inflammatory process, which
contribute to the signs and symptoms of asthma.
Dosage & Administration
Adults and adolescents
with asthma or seasonal allergic rhinitis:
Pediatric patients
with asthma or seasonal allergic rhinitis:
Use in the pediatric
patient: The safety and efficacy of Montelukast
have been established in adequate and well-controlled studies in pediatric
patients with asthma 6 months to 14 years of age. Safety and efficacy profiles
in this age group are similar to those seen in adults.
Hepatic
Insufficiency: No dosage adjustment is required in
patients with mild-to-moderate hepatic insufficiency.
Renal
Insufficiency: No dosage adjustment is recommended in
patients with renal insufficiency.
Elderly
use: The pharmacokinetic profile and the oral
bioavailability of a single 10-mg oral dose of montelukast are similar in
elderly and younger adults. The plasma half-life of montelukast is slightly
longer in the elderly. No dosage adjustment in the elderly is required.
* রেজিস্টার্ড চিকিৎসকের পরামর্শ মোতাবেক ঔষধ সেবন করুন'
Interaction
Monas has been
administered with other therapies routinely used in the prophylaxis and chronic
treatment of asthma with no apparent increase in adverse reactions. In drug
interaction studies, the recommended clinical dose of Monas did not have
clinically important effects on the pharmacokinetics of the following drugs:
theophylline, prednisone, prednisolone, oral contraceptives (norethindrone
1mg/ethinyl estradiol 35mcg), terfenadine, digoxin, and warfarin. Although
additional specific interaction studies were not performed, Monas was used
concomitantly with a wide range of commonly prescribed drugs in clinical
studies without evidence of clinical adverse interactions. These medications
included thyroid hormones, sedative hypnotics, non-steroidal anti-inflammatory
agents, benzodiazepines and decongestants. Phenobarbital, which induces hepatic
metabolism, decreased the AUC of Monas approximately 40% following a single
10mg dose of Monas. No dosage adjustment for Monas is recommended. It is
reasonable to employ appropriate clinical monitoring when potent cytochrome
P450 enzyme inducers, such as phenobarbital or rifampin, are co-administered
with Monas.
Contraindications
Montelukast is
contraindicated in patients who are hypersensitive to any component of this
product.
Side Effects
Common: Diarrhoea, fever, gastrointestinal
discomfort, headache, nausea, vomiting, skin reactions, upper respiratory tract
infection.
Uncommon: Akathisia, anxiety, arthralgia, asthenia,
abnormal behavior, depression, dizziness, drowsiness, dry mouth, haemorrhage,
irritability, malaise, muscle complaints, oedema, seizure, abnormal sensation,
sleep disorders.
Rare: Angioedema, concentration impaired,
disorientation, eosinophilic granulomatosis with polyangiitis, erythema
nodosum, hallucination, hepatic disorders, memory loss, palpitations, pulmonary
eosinophilia, suicidal tendencies, tremor.
Pregnancy & Lactation
Montelukast crosses
the placenta following oral dosing in rats and rabbits. There are, however, no
adequate and well-controlled studies in pregnant women. Because animal
reproduction studies are not always predictive of human response, Montelukast
should be used during pregnancy only if clearly needed. Because many drugs are
excreted in human milk, caution should be exercised when Montelukast is
given to a nursing mother.
Precautions & Warnings
Monas is not indicated
for use in the reversal of bronchospasm in acute asthma attacks, including
status asthmaticus. Patients should be advised to have appropriate rescue
medication available. Therapy with Monas can be continued during acute
exacerbations of asthma. While the dose of inhaled corticosteroid may be
reduced gradually under medical supervision, Monas should not be abruptly
substituted for inhaled or oral corticosteroids. Monas should not be used as
monotherapy for the treatment and management of exercise induced bronchospasm.
Patients with known aspirin sensitivity should continue avoidance of aspirin or
non-steroidal anti-inflammatory agents while taking Monas. Although Monas is
effective in improving airway function in asthmatics with documented aspirin sensitivity,
it has not been shown to truncate bronchoconstrictor response to aspirin and
other non-steroidal anti-inflammatory drugs in aspirin-sensitive asthmatic
patients.
Overdose Effects
There were no adverse
experiences in the majority of overdosage reports. The most frequently
occurring adverse experiences were consistent with the safety profile of Monas
and included abdominal pain, somnolence, thirst, headache, vomiting and
psychomotor hyperactivity. In the event of overdose, it is reasonable to employ
the usual supportive measures; e.g., remove unabsorbed material from the
gastrointestinal tract, employ clinical monitoring, and institute supportive
therapy, if required.
Therapeutic Class
Leukotriene receptor
antagonists
Storage Conditions
Store in cool &
dry place below 30°C, protect from light & moisture. Keep out of reach of
children.
Chemical Structure
Molecular Formula : |
C35H36ClNO3S |
Chemical Structure : |
Common Questions about Monas 10 mg Tablet
What is Monas 10 mg Tablet?
Monas 10 mg Tablet is a selective and orally
active leukotriene receptor antagonist.
What is Monas 10 mg Tablet used for?
Monas 10 mg Tablet is commonly used to treat
asthma or allergic rhinitis. It helps keep airways open and easy breathing by
blocking leukotrienes.
How soon can the effect of Monas 10 mg Tablet be observed?
The effect of Monas 10 mg Tablet can be
observed after 1-3 hours of administration. Monas 10 mg Tablet is not a
fast-acting rescue medicine for asthma attacks and needs to be taken daily to
work properly.
How long does the effect of Monas 10 mg Tablet last?
The effect of Monas 10 mg Tablet lasts for an
average duration of 24 hours.
Should I use Monas 10 mg Tablet empty
stomach?
Monas 10 mg Tablet may be taken with or
without food as prescribed by your doctor.
What if I miss a dose of Monas 10 mg Tablet?
If you miss a dose, you may take it as soon as
possible. But if it is almost time for your next dose, just skip that dose. Do
not double up on doses.
Are there any pregnancy warnings for Monas 10
mg Tablet?
Use of Monas 10 mg Tablet in pregnant women
should be avoided unless clearly needed.
General Instructions :
* রেজিস্টার্ড চিকিৎসকের পরামর্শ মোতাবেক ঔষধ সেবন করুন'
Login Or Registerto submit your questions to seller
No none asked to seller yet